{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:02:28Z","timestamp":1762376548577,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00212","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T04:14:59Z","timestamp":1554351299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort"],"prefix":"10.3389","volume":"9","author":[{"given":"Jeeyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Franovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukimasa","family":"Shiotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly C.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria M.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Lanman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.1038\/sj.onc.1210478","article-title":"Targeting the function of the HER2 oncogene in human cancer therapeutics","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene."},{"key":"B4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet Lond Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2011","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.3508","article-title":"Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial","author":"Siena","year":"2017","journal-title":"AACR Annu Meet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1200\/JCO.2018.36.15_suppl.3514","article-title":"KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer","volume":"36","author":"Le","year":"2018","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","article-title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","volume":"29","author":"Kim","year":"2018","journal-title":"Ann Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00059","article-title":"Prospective feasibility study for using cell-free circulating tumor DNA\u2013guided therapy in refractory metastatic solid cancers: an interim analysis","volume":"1","author":"Kim","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","article-title":"Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma","volume":"8","author":"Pectasides","year":"2018","journal-title":"Cancer Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12253-016-0082-5","article-title":"HER2 status in gastric cancer: comparison between primary and distant metastatic disease","volume":"23","author":"Amato","year":"2017","journal-title":"Pathol Oncol Res POR."},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2015.09.018","article-title":"Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1)","volume":"53","author":"Park","year":"2016","journal-title":"Eur J Cancer Oxf Engl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/jjco\/hyv020","article-title":"Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites","volume":"45","author":"Gumusay","year":"2015","journal-title":"Jpn J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS ONE."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science."},{"key":"B23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2017.35.15_suppl.108","article-title":"Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors","volume":"35","author":"Doi","year":"2017","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.2018.36.15_suppl.2500","article-title":"Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers","volume":"36","author":"Meric-Bernstam","year":"2018","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ajco.12653","article-title":"Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study","volume":"13","author":"Pathmanathan","year":"2016","journal-title":"Asia Pac J Clin Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e15099","DOI":"10.1200\/JCO.2017.35.15_suppl.e15099","article-title":"HER2 overexpression and amplification in patients with colorectal cancer: a large-scale retrospective study in Chinese population","volume":"35","author":"Ni","year":"2017","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccell.2018.06.004","article-title":"Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer","volume":"34","author":"Siravegna","year":"2018","journal-title":"Cancer Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.2018.36.15_suppl.3506","article-title":"Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer","volume":"36","author":"Bardelli","year":"2018","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB Study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e175245","DOI":"10.1001\/jamaoncol.2017.5245","article-title":"Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial","volume":"4","author":"Montagut","year":"2018","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.CD-17-1260","article-title":"Targeted therapies for targeted populations: anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma","volume":"8","author":"Maron","year":"2018","journal-title":"Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2013a randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"14093","DOI":"10.1038\/ncomms14093","article-title":"DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer","volume":"8","author":"Mamlouk","year":"2017","journal-title":"Nat Commun."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T04:15:01Z","timestamp":1554351301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":34,"alternative-id":["10.3389\/fonc.2019.00212"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00212","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"article-number":"212"}}